Filing Flows › Comparisons › DTIL vs EDIT
Precision Biosciences vs Editas Medicine: DTIL and EDIT compared
Precision Biosciences is the larger company: $10.8M of revenue in its latest quarter (Q3 FY26) against $10.4M for Editas Medicine (Q3 2026). Precision Biosciences is growing faster (374× against +37% a year earlier). Precision Biosciences is more profitable, with an operating margin of -83.7% against -234.3%.
Where the money goes: DTIL and EDIT
Precision Biosciences (DTIL) · Q3 FY26
Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%, net loss $18.4M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Editas Medicine (EDIT) · Q3 2026
Editas Medicine, Q3 2026: revenue $10.4M (+37% year over year), operating margin -234.3%, net loss $23.4M, operating cash flow −$21.2M. The chart follows the revenue to costs, profit and cash.
| Precision Biosciences (DTIL) | Editas Medicine (EDIT) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q3 2026 |
| Revenue | $10.8M | $10.4M |
| Revenue growth, Y/Y | 374× | +37% |
| Operating margin | -83.7% | -234.3% |
| Net earnings | −$18.4M | −$23.4M |
| Net margin | -170.2% | -225.7% |
| Operating cash flow | −$11.9M | −$21.2M |
Questions
Which is bigger, Precision Biosciences or Editas Medicine?
Precision Biosciences is the larger company: $10.8M of revenue in its latest quarter (Q3 FY26) against $10.4M for Editas Medicine (Q3 2026).
Is Precision Biosciences or Editas Medicine growing faster?
Precision Biosciences is growing faster (374× against +37% a year earlier).
Which is more profitable, Precision Biosciences or Editas Medicine?
Precision Biosciences is more profitable, with an operating margin of -83.7% against -234.3%.
More: Precision Biosciences earnings · how Precision Biosciences makes money · Editas Medicine earnings · how Editas Medicine makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 5, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.